Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition

Metabolism: Clinical and Experimental

Volumn 64, Issue 5, 2015, Pages 633-641

  Chang, Eugene ^a   Kim, Lisa ^b   Choi, Jung Mook ^b   Park, Se Eun ^c   Rhee, Eun Jung ^c   Lee, Won Young ^c   Oh, Ki Won ^c   Park, Sung Woo ^c   Park, Dong Il ^c   Park, Cheol Young ^b,c  

^a Ewha Womans University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

DPP 4; ERK; Ezetimibe; GLP 1; MEK

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DIPEPTIDYL PEPTIDASE IV; EZETIMIBE; GEMIGLIPTIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; AZETIDINE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; INSULIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME INHIBITION ASSAY; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; ANALYSIS; ANIMAL; BLOOD; DRUG EFFECTS; GERMFREE ANIMAL; GLUCOSE BLOOD LEVEL; INTESTINE; L CELL LINE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; AZETIDINES; BLOOD GLUCOSE; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; INSULIN; INTESTINES; L CELLS (CELL LINE); MALE; MAP KINASE SIGNALING SYSTEM; MICE; RATS; RATS, SPRAGUE-DAWLEY; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84925365910     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.02.001     Document Type: Article

References (52)

1. E.A. Schwartz, J. Koska, M.P. Mullin, I. Syoufi, D.C. Schwenke, and P.D. Reaven Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus Atherosclerosis 212 1 2010 217 222
2. W.L. Bennett, N.M. Maruthur, S. Singh, J.B. Segal, L.M. Wilson, and R. Chatterjee Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Ann Intern Med 154 9 2011 602 613
3. R.M. Elliott, L.M. Morgan, J.A. Tredger, S. Deacon, J. Wright, and V. Marks Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns J Endocrinol 138 1 1993 159 166
4. G.E. Lim, and P.L. Brubaker Glucagon-like peptide 1 secretion by the L-cell the view from within Diabetes 55 Suppl. 2 2006 S70 S77
5. D.J. Drucker The biology of incretin hormones Cell Metab 3 3 2006 153 165
6. D.A. D'Alessio, S.E. Kahn, C.R. Leusner, and J.W. Ensinck Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal J Clin Invest 93 5 1994 2263 2266
7. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study Lancet 359 9309 2002 824 830
8. K.B. Degn, B. Brock, C.B. Juhl, C.B. Djurhuus, J. Grubert, and D. Kim Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia Diabetes 53 9 2004 2397 2403
9. E. Rask, T. Olsson, S. Söderberg, J.J. Holst, A. Tura, and G. Pacini Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance Metabolism 53 5 2004 24 31
10. R. Mentlein Dipeptidyl-peptidase IV, (CD26)-role in the inactivation of regulatory peptides Regul Pept 85 1 1999 9 24
11. G. Flock, L.L. Baggio, C. Longuet, and D.J. Drucker Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice Diabetes 56 12 2007 3006 3013
12. V. Fonseca, A. Schweizer, D. Albrecht, M.A. Baron, I. Chang, and S. Dejager Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes Diabetologia 50 6 2007 1148 1155
13. P. Aschner, M.S. Kipnes, J.K. Lunceford, M. Sanchez, C. Mickel, and D.E. Williams-Herman Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 29 12 2006 2632 2637
14. M.H. Davidson, C.M. Ballantyne, B. Kerzner, L. Melani, P.T. Sager, and L. Lipka Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia Int J Clin Pract 58 8 2004 746 755
15. T. Kosoglou, P. Statkevich, A.O. Johnson-Levonas, J.F. Paolini, A.J. Bergman, and K.B. Alton Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions Clin Pharmacokinet 44 5 2005 467 494
16. L. Ge, J. Wang, W. Qi, H.H. Miao, J. Cao, and Y.X. Qu The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1 Cell Metab 7 6 2008 508 519
17. D.C. Chan, G.F. Watts, S.K. Gan, E.M. Ooi, and P.H. Barrett Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet Diabetes Care 33 5 2010 1134 1139
18. M. Yoneda, K. Fujita, Y. Nozaki, H. Endo, H. Takahashi, and K. Hosono Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study Hepatol Res 40 6 2010 566 573
19. S. Zheng, L. Hoos, J. Cook, G. Tetzloff, H. Davis, and M. van Heek Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice Eur J Pharmacol 584 1 2008 118 124
20. T. Muraoka, K. Aoki, T. Iwasaki, K. Shinoda, A. Nakamura, and H. Aburatani Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet Metabolism 60 5 2011 617 628
21. L. Jia, Y. Ma, S. Rong, J.L. Betters, P. Xie, and S. Chung Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis J Lipid Res 51 11 2010 3135 3144
22. H. Park, T. Shima, K. Yamaguchi, H. Mitsuyoshi, M. Minami, and K. Yasui Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease J Gastroenterol 46 1 2011 101 107
23. M. Deushi, M. Nomura, A. Kawakami, M. Haraguchi, M. Ito, and M. Okazaki Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome FEBS Lett 581 29 2007 5664 5670
24. S.J. Yang, J.M. Choi, L. Kim, B.J. Kim, J.H. Sohn, and W.J. Kim Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes Biochem Biophys Res Commun 407 1 2011 153 157
25. M. Igel, B.A. Taylor, S.J. Phillips, W. Becker, L. Herberg, and H.G. Joost Hyperleptinemia and leptin receptor variant Asp600Asn in the obese, hyperinsulinemic KK mouse strain J Mol Endocrinol 21 3 1998 337 345
26. R.A. Reimer Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases J Endocrinol 191 1 2006 159 170
27. G.E. Lim, G.J. Huang, N. Flora, D. LeRoith, C.J. Rhodes, and P.L. Brubaker Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell Endocrinology 150 2 2009 580 591
28. G.V. Sangle, L.M. Lauffer, A. Grieco, S. Trivedi, R. Iakoubov, and P.L. Brubaker Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue Endocrinology 153 2 2012 564 573
29. R.A. Reimer, C. Darimont, S. Gremlich, V. Nicolas-Métral, U.T. Rüegg, and K. Macé A human cellular model for studying the regulation of glucagon-like peptide-1 secretion Endocrinology 142 10 2001 4522 4528
30. C.A. Dujovne, M.P. Ettinger, J.F. McNeer, L.J. Lipka, A.P. LeBeaut, and R. Suresh Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia Am J Cardiol 90 10 2002 1092 1097
31. R.H. Knopp, C.A. Dujovne, A. Le Beaut, L.J. Lipka, R. Suresh, and E.P. Veltri Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies Int J Clin Pract 57 5 2003 363 368
32. M. Gonzalez-Ortiz, E. Martinez-Abundis, A.M. Kam-Ramos, E. Hernandez-Salazar, and M.G. Ramos-Zavala Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients Cardiovasc Drugs Ther 20 2 2006 143 146
33. M.B. Toft-Nielsen, M.B. Damholt, S. Madsbad, L.M. Hilsted, T.E. Hughes, and B.K. Michelsen Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients J Clin Endocrinol Metab 86 8 2001 3717 3723
34. T. Vilsbøll, H. Agersø, T. Krarup, and J.J. Holst Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects J Clin Endocrinol Metab 88 1 2003 220 224
35. F. Rubino, A. Forgione, D.E. Cummings, M. Vix, D. Gnuli, and G. Mingrone The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes Ann Surg 244 5 2006 741 749
36. P.V. Hojberg, T. Vilsboll, R. Rabol, F.K. Knop, M. Bache, and T. Krarup Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes Diabetologia 52 2 2009 199 207
37. E. Mannucci, A. Ognibene, F. Cremasco, G. Bardini, A. Mencucci, and E. Pierazzuoli Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects Diabetes Care 24 3 2001 489 494
38. O.G. Kolterman, J.B. Buse, M.S. Fineman, E. Gaines, S. Heintz, and T.A. Bicsak Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 88 7 2003 3082 3089
39. L. Yang, X. Li, Y. Ji, A.B. Kohan, D.Q. Wang, and P.N. Howles Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal Am J Physiol Gastrointest Liver Physiol 299 5 2010 G1003 G1011
40. K. Kikuchi, U. Nezu, K. Inazumi, T. Miyazaki, K. Ono, and K. Orime Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia J Atheroscler Thromb 19 12 2012 1093 1101
41. S.W. Park Intestinal and hepatic Niemann-Pick c1-like 1 Diabetes Metab J 37 4 2013 240 248
42. J. Yang, J. Campitelli, G. Hu, Y. Lin, J. Luo, and C. Xue Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin Life Sci 81 4 2007 272 279
43. D. Lamers, S. Famulla, N. Wronkowitz, S. Hartwig, S. Lehr, and D.M. Ouwens Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome Diabetes 60 7 2011 1917 1925
44. J. Ryskjaer, C.F. Deacon, R.D. Carr, T. Krarup, S. Madsbad, and J. Holst Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake Eur J Endocrinol 155 3 2006 485 493
45. S.A. Lee, Y.R. Kim, E.J. Yang, E.J. Kwon, S.H. Kim, and S.H. Kang CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus J Clin Endocrinol Metab 98 6 2013 2553 2561
46. R.D. Carr, M.O. Larsen, K. Jelic, O. Lindgren, J. Vikman, and J.J. Holst Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men J Clin Endocrinol Metab 95 2 2010 872 878
47. Y. Rouillé, S. Martin, and D.F. Steiner Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide J Biol Chem 270 44 1995 26488 26496
48. Y. Rouillé, S. Kantengwa, J.C. Irminger, and P.A. Halban Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1 J Biol Chem 272 52 1997 32810 32816
49. G.E. Lim, M. Xu, J. Sun, T. Jin, and P.L. Brubaker The rho guanosine 5′-triphosphatase, cell division cycle 42, is required for insulin-induced actin remodeling and glucagon-like peptide-1 secretion in the intestinal endocrine L cell Endocrinology 150 12 2009 5249 5261
50. A. Hirasawa, K. Tsumaya, T. Awaji, S. Katsuma, T. Adachi, and M. Yamada Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 Nat Med 11 1 2004 90 94
51. L. Qin, Y.B. Yang, Y.X. Yang, Y.Z. Gong, X.L. Li, and G.Y. Li Inhibition of smooth muscle cell proliferation by ezetimibe via the cyclin D1-MAPK pathway J Pharmacol Sci 125 3 2014 283 291
52. P. Muñoz-Pacheco, A. Ortega-Hernández, M. Miana, V. Cachofeiro, A. Fernández-Cruz, and D. Gómez-Garre Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism Pharmacol Res 66 6 2012 536 543